Akso Health Group ADR (AHG)vsNovartis AG ADR (NVS)
AHG
Akso Health Group ADR
$2.37
+4.37%
HEALTHCARE · Cap: $807.33M
NVS
Novartis AG ADR
$150.75
+1.44%
HEALTHCARE · Cap: $286.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 383408% more annual revenue ($56.67B vs $14.78M). NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
AHG
Avoid24
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AHG.
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$150.75
$102.13 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Areas to Watch
4.2% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : AHG
The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.50 — expect wider price swings.
AHG is growing revenue faster at 4.2% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and integrated patient care services. With a specialization in advanced health technologies, the company is well-positioned to tap into growth opportunities in telehealth and personalized medicine, bolstered by a strong commitment to research and development. Its robust business model and dedication to quality, supported by a skilled team of professionals, make Akso Health Group an appealing investment for institutional investors aiming to navigate the transformative landscape of healthcare.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?